Skip to main content
    V

    Viking Therapeutics Inc (VKTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.88
    +0.08 (+0.30%)

    Market Cap: $3.73B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Viking Therapeutics Inc (VKTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Viking Therapeutics (VKTX) has a market cap of $3.73B and an enterprise value of $3.30B. Its share count is up 5.10% from a year earlier. It holds $426.95M more cash than debt, 11.46% of its market cap.

    Total Valuation

    Enterprise value is 11.46% below the market cap, as cash exceeds debt.

    Market Cap$3.73B
    Enterprise Value$3.30B
    Latest price (Nov 17, 2026)$26.88

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.54% in the quarter ended Sep 30, 2026 and grew 3.17% a year over 2 years.

    Shares Outstanding118.05M
    Shares Change (YoY)+5.10%
    Shares Change (QoQ)+1.54%
    Share Count Growth (2Y CAGR)+3.17%

    Price Statistics

    The stock is down 31.27% over 52 weeks and trades 7.41% below its 50-day average.

    Beta (1Y)1.36
    52-Week Change-31.27%
    1-Month Change+7.31%
    3-Month Change-25.29%
    6-Month Change-5.35%
    5-Year Change+368.73%
    10-Year Change+2449.53%
    Total Return (1Y)-31.27%
    Total Return (3Y CAGR)+33.60%
    Total Return (5Y CAGR)+36.25%
    Return vs SPY (1Y)-40.37%
    Max Drawdown (1Y)-42.54%
    Max Drawdown (3Y)-78.86%
    Sharpe Ratio (1Y)-0.51
    Correlation with SPY (1Y)0.28
    50-Day Average$29.03
    200-Day Average$32.14
    52-Week Range$23.82 to $43.10
    RSI (14 Days)47.2
    Average Volume (20 Days)4.18M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.27x current liabilities, and total debt is 0.43x shareholder equity.

    Current Ratio7.27x
    Quick Ratio7.27x
    Debt / Equity0.43x

    Returns and Efficiency

    Return on invested capital is -61.05% over the last 12 months, against a 5-year average of -48.62%.

    Return on Equity (ROE)-106.56%
    Return on Assets (ROA)-64.19%
    Return on Invested Capital (ROIC)-61.05%
    ROE (5Y Average)-33.61%
    ROA (5Y Average)-30.53%
    ROIC (5Y Average)-48.62%

    Scores

    VKTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit-$94.00K
    Operating Income-$648.57M
    Pretax Income-$627.18M
    Net Income-$627.20M
    Reported EPS (TTM)-$5.40

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 60.24% of the $977.17M in total assets.

    Cash and Equivalents$677.61M
    Total Debt$250.66M
    Net Cash$426.95M
    Net Cash Per Share$3.62
    Working Capital$839.10M
    Shareholder Equity$588.60M
    Book Value Per Share$4.99
    Total Assets$977.17M
    Total Liabilities$388.57M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$462.63M
    FCF Per Share-$3.64
    Depreciation and Amortization$4.21M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+26.91%
    Tangible Book Per Share Growth (2Y CAGR)+26.91%

    Revenue and profit by year

    Dividends and Yields

    VKTX does not pay a dividend.

    Buyback Yield-9.47%
    Shareholder Yield-9.47%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About VKTX

    What is VKTX's market cap?

    Viking Therapeutics has a market cap of $3.73B. Its enterprise value, which adds debt and subtracts cash, is $3.30B.

    How many shares of VKTX are outstanding?

    Viking Therapeutics has 118.05M shares outstanding. The count is up 5.10% from a year earlier.

    Does VKTX pay a dividend?

    No. Viking Therapeutics does not pay a dividend.

    How much debt does VKTX have?

    Viking Therapeutics has $250.66M of total debt and $677.61M of cash and equivalents, a net cash position of $426.95M.